Neovasc (NASDAQ:NVCN) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.
Earnings and Valuation
This table compares Neovasc and Sintx Technologies’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Neovasc||$1.75 million||14.98||-$108.04 million||($27.30)||-0.10|
|Sintx Technologies||$90,000.00||20.96||-$8.65 million||N/A||N/A|
Sintx Technologies has lower revenue, but higher earnings than Neovasc.
Volatility and Risk
Neovasc has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Sintx Technologies has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500.
This is a breakdown of current recommendations for Neovasc and Sintx Technologies, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Neovasc presently has a consensus target price of $9.00, indicating a potential upside of 239.62%. Sintx Technologies has a consensus target price of $3.00, indicating a potential upside of 287.10%. Given Sintx Technologies’ higher possible upside, analysts clearly believe Sintx Technologies is more favorable than Neovasc.
Institutional and Insider Ownership
11.5% of Neovasc shares are owned by institutional investors. Comparatively, 3.3% of Sintx Technologies shares are owned by institutional investors. 0.3% of Sintx Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares Neovasc and Sintx Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Neovasc beats Sintx Technologies on 6 of the 11 factors compared between the two stocks.
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
About Sintx Technologies
Sintx Technologies, Inc., a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, and South America. The company offers ceramic based biomaterial solutions in various medical and industrial applications. It provides spine implant products under the Valeo brand to surgeons and hospitals for use in cervical and thoracolumbar spine surgery. The company markets and sells its products directly; and through direct sales organizations, distributors, as well as original equipment manufacturer and private label partnerships. Sintx Technologies, Inc. has a collaboration agreement with CTL Amedica to design and launch spinal implants. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies, Inc. in October 2018. Sintx Technologies, Inc. was founded in 1996 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.